Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of medical genetics. Part A 2019-06, Vol.179 (6), p.1069-1073
Hauptverfasser:	Hughes, Derralynn A., Nicholls, Kathleen, Sunder‐Plassmann, Gere, Jovanovic, Ana, Feldt‐Rasmussen, Ulla, Schiffmann, Raphael, Giugliani, Robert, Jain, Vipul, Viereck, Chris, Castelli, Jeffrey P., Skuban, Nina, Barth, Jay A., Bichet, Daniel G.
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Deoxynojirimycin - administration & dosage 1-Deoxynojirimycin - adverse effects 1-Deoxynojirimycin - analogs & derivatives 1-Deoxynojirimycin - therapeutic use alpha-Galactosidase - administration & dosage alpha-Galactosidase - therapeutic use Drug Substitution Enzyme Replacement Therapy - methods Fabry Disease - diagnosis Fabry Disease - genetics Fabry Disease - metabolism Fabry Disease - therapy Fabry's disease Female Humans Male Research Letter Research Letters
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!